Therefore, the efficacy of the combined opposite targeting of p110δ PI3K and RhoA in preventing melanoma tumour growth and metastasis strongly provides a major advance for designing new successful therapies and for considering the use of p110δ-selective inhibitors as combinatorial regimens in melanoma treatment. This evidence concerns the gene PIK3CD and neoplasm.